NanoEcho has published its interim report for the first quarter of 2025, highlighting several important advancements. The dose-confirmation study has been successfully completed with the primary endpoints achieved, and the collected data is now being used to optimise the system ahead of the next phase of the clinical programme. The rights issue carried out during the quarter enabled both the completion of the study and the start of the next stage of development.
At the same time, the health economic value of the method has been confirmed in a published scientific analysis, and positive results from an external Phase III MRI study on prostate cancer further validate the effectiveness of the selected nanoparticle in medical diagnostics.
The full quarterly report is available here (in Swedish)
Watch CEO Linda Persson summarise the quarter in the video below (subtitled in English)
